Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ)
CNY8.71
+0.26 (+3.08%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 1 Xianyao Road 317300
Xianju, CN
Xianju, CN
CEO
Weihua Jin
Website
xjpharma.com
IPO
2010-01-12
ISIN CNE100000K64
Description
Zhejiang Xianju Pharmaceutical Co.,Ltd. is a global enterprise specializing in the production and distribution of steroidal and hormonal pharmaceutical products. Its offerings span active pharmaceutical ingredients (APIs), specifically steroid-based medications and both male and female hormones, alongside various chemical intermediates. The company also provides a comprehensive selection of finished dosage forms, including tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-for-injection preparations. Established in 1972, Zhejiang Xianju Pharmaceutical Co.,Ltd. operates from its headquarters in Xianju, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY8.71
+0.26 (+3.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
0.24
Float Shares
775.98M
Free Float %
78.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.94% | -1.64% | -4.54% | -10.53% | -9.28% | -6.66% | -9.76% | -45.32% | -38.84% | +25.71% | -5.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8.71
DCF (Unlevered)
17.50
+100.9%
DCF (Levered)
8.65
-0.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | -2 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.00
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-6.0% Q1'26: -8.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+12.5% Q1'26: -34.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+0.0% Q1'26: +10.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.4% ★ Q1'26: +11.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.0% ★ Q1'26: +7.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.22× ★ Q1'26: 0.40× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.48B
est: 2.43B (+1.9%)
|
2.50B
est: 2.58B (-2.9%)
|
2.85B
est: 2.80B (+2.0%)
|
3.62B
est: 3.65B (-0.8%)
|
3.71B
est: 3.71B (-0.1%)
|
4.02B
est: 4.02B (+0.1%)
|
4.36B
est: 4.34B (+0.5%)
|
4.38B
est: 4.40B (-0.4%)
|
4.12B
est: 4.31B (-4.2%)
|
4.00B
est: 4.26B (-6.1%)
|
3.76B
est: 3.94B (-4.5%)
|
4.01B
3.98B – 4.04B
+1.8% YoY
|
4.34B
4.23B – 4.44B
+8.2% YoY
|
4.89B
4.81B – 4.96B
+12.7% YoY
|
| EBITDA |
250.12M
est: 489.01M (-48.9%)
|
283.58M
est: 518.30M (-45.3%)
|
431.91M
est: 561.81M (-23.1%)
|
605.18M
est: 733.32M (-17.5%)
|
697.36M
est: 745.78M (-6.5%)
|
817.16M
est: 806.73M (+1.3%)
|
857.11M
est: 871.34M (-1.6%)
|
866.26M
est: 883.17M (-1.9%)
|
816.24M
est: 864.91M (-5.6%)
|
835.24M
est: 855.79M (-2.4%)
|
763.05M
est: 790.51M (-3.5%)
|
804.97M
799.35M – 810.60M
+1.8% YoY
|
870.75M
849.56M – 891.94M
+8.2% YoY
|
981.11M
965.41M – 996.81M
+12.7% YoY
|
| EBIT |
158.96M
est: 374.68M (-57.6%)
|
191.34M
est: 397.12M (-51.8%)
|
335.53M
est: 430.46M (-22.1%)
|
478.75M
est: 561.87M (-14.8%)
|
562.24M
est: 571.41M (-1.6%)
|
640.05M
est: 618.11M (+3.5%)
|
672.92M
est: 667.62M (+0.8%)
|
678.81M
est: 676.69M (+0.3%)
|
604.79M
est: 662.69M (-8.7%)
|
617.42M
est: 642.73M (-3.9%)
|
540.49M
est: 593.71M (-9.0%)
|
604.57M
600.35M – 608.79M
+1.8% YoY
|
653.97M
638.06M – 669.89M
+8.2% YoY
|
736.86M
725.07M – 748.65M
+12.7% YoY
|
| Net Income |
106.55M
est: 112.53M (-5.3%)
|
146.19M
est: 158.87M (-8.0%)
|
206.63M
est: 258.17M (-20.0%)
|
301.36M
est: 342.57M (-12.0%)
|
410.37M
est: 436.90M (-6.1%)
|
504.51M
est: 506.40M (-0.4%)
|
619.33M
est: 615.63M (+0.6%)
|
749.41M
est: 744.71M (+0.6%)
|
563.08M
est: 645.42M (-12.8%)
|
397.18M
est: 689.15M (-42.4%)
|
449.64M
est: 514.39M (-12.6%)
|
469.87M
464.93M – 474.82M
-8.7% YoY
|
544.06M
532.75M – 555.38M
+15.8% YoY
|
613.31M
600.55M – 626.07M
+12.7% YoY
|
| SGA |
871.94M
est: 820.92M (+6.2%)
|
1.04B
est: 870.09M (+19.4%)
|
1.12B
est: 943.12M (+19.0%)
|
1.45B
est: 1.23B (+18.0%)
|
1.41B
est: 1.25B (+12.7%)
|
1.34B
est: 1.35B (-0.8%)
|
1.56B
est: 1.46B (+6.6%)
|
1.53B
est: 1.48B (+3.4%)
|
1.27B
est: 1.45B (-12.4%)
|
1.34B
est: 1.40B (-4.3%)
|
1.11B
est: 1.30B (-14.2%)
|
1.32B
1.31B – 1.33B
+1.8% YoY
|
1.43B
1.39B – 1.46B
+8.2% YoY
|
1.61B
1.58B – 1.64B
+12.7% YoY
|
| EPS |
0.13
est: 0.11 (+14.7%)
|
0.16
est: 0.16 (+0.0%)
|
0.23
est: 0.26 (-11.5%)
|
0.33
est: 0.35 (-4.3%)
|
0.45
est: 0.44 (+2.3%)
|
0.51
est: 0.51 (+0.0%)
|
0.63
est: 0.62 (+1.0%)
|
0.76
est: 0.75 (+1.3%)
|
0.57
est: 0.65 (-12.3%)
|
0.40
est: 0.70 (-42.6%)
|
0.45
est: 0.52 (-13.5%)
|
0.48
0.47 – 0.48
-8.7% YoY
|
0.55
0.54 – 0.56
+15.8% YoY
|
0.62
0.61 – 0.63
+12.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
19.58M
OE per share TTM
0.02
Owner's Yield
0.24%
Maintenance CapEx ratio
98.36%
Maint CapEx / Avg PPE
54.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 23 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 41.0K | 0.49% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 51.9K | 0.65% |
| 3 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 77.0K | 0.24% |
| 4 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 77.0K | 0.24% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 57.6K | 0.46% |
| 6 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 398.0K | 0.07% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 307.8K | 0.06% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 183.5K | 0.39% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 84.0K | 0.29% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 92.7K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
164.7K
Shares Outstanding
989.20M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carlo Cartasegna | Deputy General Manager | — | male |
| Wangwei Zhang | Deputy GM, Secretary & Director | — | male |
| Weihua Jin | GM & Director | — | male |
| Wen Hui Zou | Deputy General Manager | — | male |
| Yao Hua Wang | Chief Financial Officer, Financial Director & Chief Accountant | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002332.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
